IL18 and glioblastoma: Thus, there is potential for the suggested combination of disulfiram and ritonavir to reduce an immune response to glioblastoma cells, but if the preponderant effect of IL-18 is to stimulate centrifugal migration, the net effect may well be clinically beneficial.